Literature DB >> 26891998

National Lipid Association Annual Summary of Clinical Lipidology 2016.

Harold E Bays1, Peter H Jones2, Carl E Orringer3, W Virgil Brown4, Terry A Jacobson5.   

Abstract

The National Lipid Association (NLA) Annual Summary of Clinical Lipidology is a yearly updated summary of principles important to the patient-centered evaluation, management, and care of patients with dyslipidemia. This summary is intended to be a "living document," with future annual updates based on emerging science, clinical considerations, and new NLA Position, Consensus, and Scientific Statements, thus providing an ongoing resource that applies the latest in medical science towards the clinical management of patients with dyslipidemia. Topics include the NLA Recommendations for Patient-Centered Management of Dyslipidemia, genetics, Familial Hypercholesterolemia, secondary causes of dyslipidemia, biomarkers and advanced lipid testing, nutrition, physical activity, obesity, adiposopathy, metabolic syndrome, diabetes mellitus, lipid pharmacotherapy, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia management and treatment based upon age (children, adolescents, and older individuals), dyslipidemia considerations based upon race, ethnicity and gender, dyslipidemia and human immune virus infection, dyslipidemia and immune disorders, adherence strategies and collaborative care, and lipid-altering drugs in development. Hyperlinks direct the reader to sentinel online tables, charts, and figures relevant to lipidology, access to online atherosclerotic cardiovascular disease risk calculators, worldwide lipid guidelines, recommendations, and position/scientific statements, as well as links to online audio files, websites, slide shows, applications, continuing medical education opportunities, and patient information.
Copyright © 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Annual Summary; Cholesterol; Clinical Lipidology; Dyslipidemia; Guidelines; National Lipid Association; Recommendations

Mesh:

Substances:

Year:  2016        PMID: 26891998     DOI: 10.1016/j.jacl.2015.08.002

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  25 in total

1.  Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia.

Authors:  Ruth Cano-Corres; Beatriz Candás-Estébanez; Ariadna Padró-Miquel; Marta Fanlo-Maresma; Xavier Pintó; Pedro Alía-Ramos
Journal:  J Clin Lab Anal       Date:  2018-05-07       Impact factor: 2.352

Review 2.  Genetics of Dyslipidemia and Ischemic Heart Disease.

Authors:  Kavita Sharma; Ragavendra R Baliga
Journal:  Curr Cardiol Rep       Date:  2017-05       Impact factor: 2.931

3.  Serum Lipids and Lipoproteins During Uncomplicated Malaria: A Cohort Study in Lambaréné, Gabon.

Authors:  Benjamin J Visser; Sophia G de Vries; Rieke Vingerling; Martin Gritter; Danielle Kroon; Lídia Ciudad Aguilar; Rik B J Kraan; Rosanne W Wieten; François Danion; Barbara Sjouke; Akim A Adegnika; Selidji T Agnandji; Peter G Kremsner; Thomas Hänscheid; Petra F Mens; Michèle van Vugt; Martin P Grobusch
Journal:  Am J Trop Med Hyg       Date:  2017-05       Impact factor: 2.345

4.  Clinical Utility of Amplification Refractory Mutation System-Based PCR and Mutation-Specific PCR for Precise and Rapid Genotyping of Angiotensin-Converting Enzyme 1 (ACE1-rs4646996 D>I) and Angiotensin-Converting Enzyme 2 (ACE2-rs4240157T>C) Gene Variations in Coronary Artery Disease and Their Strong Association with Its Disease Susceptibility and Progression.

Authors:  Aadil Yousif; Rashid Mir; Jamsheed Javid; Jameel Barnawi; Mohammed M Jalal; Malik A Altayar; Salem Owaid Albalawi; Faisel M Abuduhier
Journal:  Diagnostics (Basel)       Date:  2022-05-26

Review 5.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

6.  Tooth Loss and Metabolic Syndrome in South Korea: The 2012 Korean National Health and Nutrition Examination Survey.

Authors:  Si-Wan Kim; Kyung-Hwan Cho; Kyung-Do Han; Yong-Kyun Roh; In-Seok Song; Yang-Hyun Kim
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

7.  Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.

Authors:  L A Leiter; D Müller-Wieland; M T Baccara-Dinet; A Letierce; R Samuel; B Cariou
Journal:  Diabet Med       Date:  2017-08-31       Impact factor: 4.359

8.  Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Authors:  Dirk Müller-Wieland; Lawrence A Leiter; Bertrand Cariou; Alexia Letierce; Helen M Colhoun; Stefano Del Prato; Robert R Henry; Francisco J Tinahones; Lisa Aurand; Jaman Maroni; Kausik K Ray; Maja Bujas-Bobanovic
Journal:  Cardiovasc Diabetol       Date:  2017-05-25       Impact factor: 9.951

9.  Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.

Authors:  Harold E Bays; Lawrence A Leiter; Helen M Colhoun; Desmond Thompson; Laurence Bessac; Robert Pordy; Peter P Toth
Journal:  J Am Heart Assoc       Date:  2017-08-08       Impact factor: 5.501

10.  Adropin: An endocrine link between the biological clock and cholesterol homeostasis.

Authors:  Sarbani Ghoshal; Joseph R Stevens; Cyrielle Billon; Clemence Girardet; Sadichha Sitaula; Arthur S Leon; D C Rao; James S Skinner; Tuomo Rankinen; Claude Bouchard; Marinelle V Nuñez; Kimber L Stanhope; Deborah A Howatt; Alan Daugherty; Jinsong Zhang; Matthew Schuelke; Edward P Weiss; Alisha R Coffey; Brian J Bennett; Praveen Sethupathy; Thomas P Burris; Peter J Havel; Andrew A Butler
Journal:  Mol Metab       Date:  2017-12-30       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.